ATEZOLIZUMAB PLUS VEMURAFENIB AND COBIMETINIB PROVIDES FAVORABLE SURVIVAL OUTCOMES IN PATIENTS WITH HIGH TUMOR MUTATION BURDEN AND PROINFLAMMATORY GENE SIGNATURE IN THE PHASE 3 IMSPIRE150 STUDY

Lewis, KarlAscierto, PaoloRobert, CarolineMunhoz, RodrigoLiszkay, GabriellaDe La Cruz Marino, LuisOlah, JuditQueirolo, PaolaMackiewicz, JacekShah, KalpitForbes, HarperHertig, ChristianYan, YibingGutzmer, RalfMcArthur, Grant2025-01-072025-01-072020-11-01https://hdl.handle.net/10668/27584enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/ATEZOLIZUMAB PLUS VEMURAFENIB AND COBIMETINIB PROVIDES FAVORABLE SURVIVAL OUTCOMES IN PATIENTS WITH HIGH TUMOR MUTATION BURDEN AND PROINFLAMMATORY GENE SIGNATURE IN THE PHASE 3 IMSPIRE150 STUDYconference outputopen access10.1136/jitc-2020-SITC2020.03072051-1426https://jitc.bmj.com/content/jitc/8/Suppl_3/A188.2.full.pdf616665300299